InChI key
FTALBRSUTCGOEG-UHFFFAOYSA-N
InChI
1S/C8H5F3N2OS/c9-8(10,11)14-4-1-2-5-6(3-4)15-7(12)13-5/h1-3H,(H2,12,13)
SMILES string
Nc1nc2ccc(OC(F)(F)F)cc2s1
正在寻找类似产品? 访问 产品对比指南
Biochem/physiol Actions
Glutamate release inhibitor
signalword
Danger
hcodes
pcodes
Hazard Classifications
Acute Tox. 2 Oral
存储类别
6.1A - Combustible acute toxic Cat. 1 and 2 / very toxic hazardous materials
wgk
WGK 3
ppe
Eyeshields, Faceshields, Gloves, type P2 (EN 143) respirator cartridges
法规信息
新产品
此项目有
Mark C Bellingham
Journal of neurophysiology, 110(5), 1047-1061 (2013-06-07)
Riluzole is the sole treatment for amyotrophic lateral sclerosis (ALS), but its therapeutically relevant actions on motor neurons are not well defined. Whole cell patch-clamp recordings were made from hypoglossal motor neurons (HMs, n = 25) in brain stem slices
Shahriar Koochekpour et al.
Clinical cancer research : an official journal of the American Association for Cancer Research, 18(21), 5888-5901 (2012-10-18)
During glutaminolysis, glutamine is catabolized to glutamate and incorporated into citric acid cycle and lipogenesis. Serum glutamate levels were measured in patients with primary prostate cancer or metastatic castrate-resistant prostate cancer (mCRPCa) to establish clinical relevance. The effect of glutamate
Steve Vucic et al.
Brain : a journal of neurology, 136(Pt 5), 1361-1370 (2013-04-26)
Riluzole, a benzothiazole derivative, has been shown to be effective in prolonging survival in amyotrophic lateral sclerosis. The mechanisms by which riluzole exerts neuroprotective effects in amyotrophic lateral sclerosis remains to be fully elucidated, although inhibition of glutamatergic transmission and
Christopher Pittenger et al.
CNS drugs, 22(9), 761-786 (2008-08-14)
Recent advances implicate amino acid neurotransmission in the pathophysiology and treatment of mood and anxiety disorders. Riluzole, which is approved and marketed for the treatment of amyotrophic lateral sclerosis, is thought to be neuroprotective through its modulation of glutamatergic neurotransmission.
Diana S L Chow et al.
Journal of neurosurgery. Spine, 17(1 Suppl), 129-140 (2012-09-19)
The aim of this paper was to characterize individual and population pharmacokinetics of enterally administered riluzole in a Phase 1 clinical trial of riluzole as a neuroprotective agent in adults 18-70 years old with acute spinal cord injury (SCI). Thirty-five
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持